In a phase 2 trial in participants with obesity and MASLD, once-weekly treatment with the GIP/GLP-1/GCG triple agonist retatrutide resulted in substantial reductions in liver fat, body weight, abdominal visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT), serum lipids
[DOI] [PubMed] [Google Scholar] 41.Evans MD, Cooke MS, Akil M, Samanta A, Lunec J
B12 reduces circulating levels of homocysteine, a compound linked to increased risk of heart attack and stroke
[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Wang C., Zhang B., Zhang H., Yang W., Meng Q., Shi B., Shan A
Lapatinib is approved for the treatment of ErbB2-positive breast cancer and other cancers that overexpress ErbB2
Suporte na sade cardiovascular